Please assess the completion status of the following clinical trial:

Trial Title: Systemic Therapy With or Without Upfront Transarterial Embolization for Inoperable Liver Metastasis of Neuroendocrine Tumors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of NET of gastroenteropancreatic (GEP), pulmonary or unknown primary site origin~* Unresectable liver metastases, according the judgment of surgeon, (the reasons for the opinion of surgeon should be made explicit)~* Hepatic involvement ≤50% volume of the organ~* Radiological evidence of hepatic lesions (contemporaneous progression or appearance of extrahepatic lesions are allowed if not critical sites) that require change or initiation of systemic pharmacotherapy~* Patients undergoing , previously treated , or never treated with systemic medical therapy are eligible~* Patients with or without carcinoid syndrome are eligible~* Well (G1) or medium (G2) differentiated histology (according to WHO 2010 classification)~* Ki67 ≤ 20% (G1-G2)~* Life expectancy \> 6 months~* Age ≥ 18 and \< 80 years~Exclusion Criteria:~* Previous loco-regional post-surgical treatment~* Poorly differentiated histology~* Severe concomitant morbidities such as: severe coagulopathy, severe liver failure (to be detailed), renal failure (creatinine \> 2.0 mg/dl) and heart failure (NYHA 3-4 or unstable ischemic heart disease), contraindicating the interventional procedure or influencing the general prognosis (Investigator to provide details of exclusion)~* Extrahepatic metastasis in critical locations as: brain, spinal cord, lung with respiratory impairment, symptomatic vertebral lesions~* Patients with only extra-hepatic lesions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Pharmacologic therapy (Type: ACTIVE_COMPARATOR): Patients in this arm receive systemic pharmacologic therapy alone
- TAE and pharmacologic therapy (Type: EXPERIMENTAL): Patients in this arm receive systemic pharmacologic therapy and TAE

Based on this trial design, predict the completion outcome and termination type (if applicable).